Eli Lilly & Co (LLY) DIvidends Date & History

Key Takeaways

• LLY pays a quarterly dividend of $1.73 per share, annualizing to $6.92.
• Current dividend yield stands at approximately 0.62%.
• Payout ratio remains low at around 22-24%, supporting sustainability.
• Dividend increases have occurred for 11 consecutive years with recent annual growth near 15%.
• Free cash flow coverage is robust, with strong earnings supporting ongoing payments.
• The stock appeals primarily to dividend growth investors rather than high-income seekers.

Dividend Overview

Eli Lilly and Company (LLY) follows a quarterly dividend payment schedule. The company currently distributes $1.73 per share each quarter, resulting in an annual total of $6.92. This translates to a dividend yield of roughly 0.62% based on recent share prices. LLY is best characterized as a dividend growth stock with a modest yield, prioritizing consistent increases over high current income. The policy reflects a conservative approach that aligns payouts with strong earnings growth in the pharmaceutical sector.

Dividend History and Growth

LLY has maintained a track record of dividend increases for 11 consecutive years. Recent annual growth rates have averaged approximately 15%, with the quarterly payout rising from $1.30 in 2024 to $1.73 in 2026. Historical data shows steady progression, including increases from $0.98 in 2022 to $1.13 in 2023 and further adjustments in subsequent years. This pattern demonstrates a long-term strategy of rewarding shareholders through reliable growth rather than aggressive yield expansion.

Dividend Sustainability and Payout Ratio

The dividend appears highly sustainable. The payout ratio hovers between 22% and 24%, well below typical thresholds for concern and supported by earnings per share exceeding $28 in recent periods. Free cash flow has shown significant improvement, reaching multi-billion-dollar levels annually, providing ample coverage for distributions. Low debt relative to cash generation and robust operating margins further bolster the company’s ability to maintain and grow dividends without strain.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, LLY’s yield of approximately 0.62% is lower than peers such as Johnson & Johnson (around 2.1%) and AbbVie (near 2.8%). However, its dividend growth rate significantly outpaces many competitors, reflecting stronger recent earnings expansion. This positions LLY as a lower-yield but higher-growth option compared to more mature, income-focused pharmaceutical companies.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener.

Is This Stock Attractive for Dividend Investors?

LLY suits dividend growth investors seeking long-term compounding through consistent increases rather than immediate high income. Its low payout ratio, strong free cash flow, and history of annual raises make it appealing for those with a multi-year horizon focused on capital appreciation alongside modest but growing distributions. Income-oriented investors prioritizing higher current yields may find better options elsewhere in the sector. The profile aligns with conservative growth strategies but requires tolerance for a lower starting yield amid elevated share valuations. All analysis remains factual and does not constitute investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations